Mutation and expression of multiple treatment response-related genes in a population with locally advanced non-small cell lung cancer

Oncology Letters

Volumn 3, Issue 2, 2012, Pages 415-420

  Lu, Hong Yang ^a   Su, Dan ^a   Pan, Xiao Dan ^a   Jiang, Hong ^a   Ma, Sheng Lin ^b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Expression; Gene mutation; Locally advanced non small cell lung cancer; Treatment response related genes

Indexed keywords

B RAF KINASE; BETA TUBULIN; BETA TUBULIN 3; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; K RAS PROTEIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC ALPHA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CODON; DNA MICROARRAY; EXON; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; SOMATIC MUTATION;

EID: 84855220707     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.502     Document Type: Article

References (21)

1. O'Rourke N and Macbeth F: Is concurrent chemoradiation the standard of care for locally advanced non-small cell lung cancer? A review of guidelines and evidence. Clin Oncol 22: 347-355, 2010.
2. Douillard JY, Shepherd FA, Hirsh V, et al: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28: 744-752, 2010.
3. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
4. Vilmar A, Santoni-Rugiu E and Sørensen JB: ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer 46: 1554-1562, 2010.
5. Sève P, Mackey J, Isaac S, et al: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4: 2001-2007, 2005.
6. Joerger M, Omlin A, Cerny T, et al: The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Target 11: 37-47, 2010.
7. Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967, 2009.
8. Wu YL, Zhong WZ, Li LY, et al: Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2: 430-439, 2007.
9. Dahabreh IJ, Linardou H, Siannis F, et al: Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 16: 291-303, 2010.
10. Martinez E, Martinez M, Viñolas N, et al: Feasibility and tolerability of the addition of erlotinib to 3D thoracic radiotherapy (RT) in patients (p) with unresectable NSCLC: a prospective randomized phase II study. J Clin Oncol 26 (Suppl): 7563, 2008.
11. Slebos RJ, Kibbelaar RE, Dalesio ON, et al: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323: 561-565, 1990.
12. Mascaux C, Iannino N, Martin B, et al: The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92: 131-139, 2005.
13. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352: 2589-2597, 2005.
14. Gautschi O, Huegli B, Ziegler A, et al: Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett 254: 265-273, 2007.
15. Jackman DM, Miller VA, Cioffredi LA, et al: Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 15: 5267-5273, 2009.
16. Naoki K, Chen TH, Richards WG, et al: Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 62: 7001-7003, 2002.
17. Okudela K, Suzuki M, Kageyama S, et al: PIK3CA mutation and amplification in human lung cancer. Pathol Int 57: 664-671, 2007.
18. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006.
19. Ceppi P, Volante M, Saviozzi S, et al: Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107: 1589-1596, 2006.
20. Govindan R, Bogart J, Wang X, et al: Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Clin Oncol 27 (Suppl): 7505, 2009.
21. Shenglin M, Yaping X, Yongling J, et al: Concomitant pemetrexed/carboplatin chemotherapy and 3D conformal radiotherapy followed by pemetrexed/carboplatin consolidation chemotherapy for locally advanced non-small cell lung cancer: preliminary results of a phase II study. J Clin Oncol 28 (Suppl): 7092, 2010.